Skip to main content

MoneyWorks4Me

Suven Life Sciences informs about press release

24 Sep 2019 Evaluate

Suven Life Sciences has informed that it has enclosed Press Release of the company titled First Patient randomized in a Phase 2A, Proof of Concept (PoC) clinical trial of SUVN-G3031 for the treatment of Narcolepsy associated with or without Cataplexy in USA.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1762.95
Dr. Reddys Labs. 1338.50
Cipla 1357.00
Lupin 1998.00
Zydus Lifesciences 1186.00
View more..